Q-omics provides the consensus-scored BCAP29 profile across patient tissues and cancer cell-line models. BCAP29 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BCAP29 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, BCAP29 protein abundance shows 20,149 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, THCA, and GBM as cancer lineages where BCAP29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCAP29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCAP29 survival associations across molecular data types. BCAP29 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCAP29 RNA expression–survival associations across cancer types. High BCAP29 expression shows unfavorable associations in ACC, HNSC, UVM, KIRP and MESO, but favorable associations in COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BCAP29 RNA expression.
This table summarizes BCAP29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for BCAP29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCAP29 shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, LIHC, HNSC and KIRP. The THCA box plot shows higher BCAP29 RNA expression in normal versus tumor tissue (log2 FC = −1.687, t-test p < 0.001).
This table shows molecular features associated with BCAP29 in patient tissues and cancer cell lines. In patient samples, BCAP29 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BCAP29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
